Business Context and Reporting Period
This Form 8-K filing by Alector, Inc. (ALEC) reports on events occurring on March 5, 2020. The company is a biopharmaceutical firm incorporated in Delaware and listed on the NASDAQ Global Select Market. The report specifically addresses Item 5.02 regarding the appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved annual base salary increases and target cash incentive compensation percentages for 2020, effective March 1, 2020. The changes for named executive officers are as follows:
- Arnon Rosenthal, Ph.D. (CEO): Base salary increased by $35,000 to $560,000; target cash incentive set at 55% of base salary.
- Calvin Yu (VP, Finance): Base salary increased by $39,400 to $300,000; target cash incentive set at 30% of base salary.
- Robert Paul, M.D. (CMO): Base salary increased by $47,900 to $440,000; target cash incentive set at 40% of base salary.
- Robert King, Ph.D. (CDO): Base salary increased by $62,500 to $425,000; target cash incentive set at 40% of base salary.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It references a prospectus filed on January 30, 2020, for details on the cash executive incentive compensation plan.
Investor Verification Checklist
- Verify the total annual compensation cost impact of these salary increases and incentive plans on the company's operating expenses.
- Review the January 30, 2020 prospectus to understand the specific performance metrics tied to the target cash incentive percentages.
- Confirm if these compensation adjustments align with the company's current cash runway and funding status given the lack of revenue.